Volume 94 Issue 30
Issue Date: July 25, 2016
p. 17 ConcentratesIssue Date: July 25, 2016
Juno acquires RedoxTherapies
Juno Therapeutics has acquired RedoxTherapies for $10 million in cash and potential milestone payments. With the deal comes vipadenant, a small-molecule adenosine A2A receptor antagonist that has the potential to inhibit immunosuppressive pathways in cancer. Juno intends to test the molecule in combination with its engineered T-cell candidates. Only a few days before announcing the acquisition, Juno was allowed to restart a Phase II leukemia clinical trial of its lead product candidate, JCAR015. FDA had halted the trial when two patients died after the addition of another drug to the treatment regimen.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society
Leave A Comment